Investors

Corporate Overview

We are a biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases.

Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immunity responses. EB05 (paridiprubart) inhibits Toll-like receptor 4 (TLR4), a key immune signaling protein and an important mediator of inflammation. We are currently evaluating EB05 as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life threatening form of respiratory failure. Based in part on the Phase 2 results  of our Phase 2/3 study, the U.S. FDA granted us Fast Track designation. To receive this designation, drug candidates must both treat a serious disease and have non-clinical or clinical data that demonstrate the potential to address an unmet medical need.

We are also developing product candidates for a number of chronic dermatological and inflammatory conditions. We recently reported topline results of a Phase 2b study of our EB01 (daniluromer) drug candidate in moderate-to-severe chronic Allergic Contact Dermatitis (ACD), a common, often work-related skin condition. We have an approved clinical trial application for our EB06 monoclonal antibody candidate to conduct a future Phase 2 study in vitiligo. We are also preparing an IND for our EB07 product candidate (paridiprubart) to conduct a future Phase 2 study in systemic sclerosis (SSc).